PRiME Connaught Global Challenge Series: Symposium with The Hebrew University of Jerusalem

Following the success of last December’s PRiME-UCSF joint symposium, PRiME is hosting the second instalment of the Connaught Global Challenge Series introducing our partnership with the Hebrew University of Jerusalem (HUJI). This will be a three-part event, featuring investigators from both UofT and HUJI who are working at the forefront of protein engineering, molecular diagnostics, and drug delivery. Additional information along with the full program for each session is provided below.

Late last year, PRiME kicked off its new global partnerships program, funded by a Connaught Global Challenge Award, with a two-day session, featuring both PRiME and UCSF investigators conducting research in proteostasis and high-throughput technologies. These stimulating discussions not only showcased the wealth of talent and innovation from both institutions, but also provided a forum to identify potential collaborative efforts between individual investigators across the two sites. It is with these partnerships, and with an international and inter-disciplinary approach to sharing knowledge and insights, that we will aim to advance biomedical innovation.

For those who missed the PRiME-UCSF symposium, the entire event can be viewed on PRiME’s YouTube channel at this link.

Program details are below.  Please note that advanced registration is required for attendance.

NOTE: This event has already taken place. You can watch this seminar series on PRiME’s YouTube channel.

PRiME - HUJI Mini-Symposium

Wednesday February 24th, March 3rd & March 10th, 2021

All days start at 9:00am EST & 4:00pm IST; separate registration is required for each event in the series.

All times indicated are EST. Event will be held online.

Wednesday, February 24th

Session 1: Protein Design, Protein-Drug Interactions, and Protein Engineering

9:00 – 9:15      Introduction to PRiME and the Connaught Global Challenge Program

9:15 – 9:35      Amiram Goldblum, HUJI

Multitargeting: discovering single molecules that simultaneously hit a few disease targets

9:35 – 9:55      Frank Sicheri, UofT

Engineering and characterization of a PROTAC against oncogenic BRAF kinase

10:00 – 10:20      Julia Shifman, HUJI

Engineering of protein-based drugs against cancer and COVID-19”

10:20 – 10:40      Stephane Angers, UofT

Promoting stem cell activity using proximity-inducing antibodies for tissue regeneration

10:40 – 11:00      Ora Furman-Schueler, HUJI

Accurate structural characterization of peptide-mediated interactions as a starting point for drug design

11:00 – 11:20      Scott Prosser, UofT

NMR studies of the Adenosine A2A Receptor G protein complex: Addressing the Mechanism of Activation of GPCRs

11:20 – 12:00       Questions & open discussion

Wednesday, March 3rd

Session 2: Molecular Diagnostics

9:00 – 9:15      Introduction to PRiME and the Connaught Global Challenge Program

9:15 – 9:35      Eylon Yavin, HUJI

FIT-PNAs: RNA sensors in humans and parasites

9:35 – 9:55      Keith Pardee, UofT

RESPONDING TO OUTBREAKS: An emerging role for synthetic biology and low-cost hardware

10:00 – 10:20      Galia Blum, HUJI

Disease detection using protease activity probes

10:20 – 10:40      Aaron Wheeler, UofT

Digital Microfluidic Systems for Serological Surveillance in the Field

10:40 – 11:00      Katy Margulis, HUJI

Mass spectrometry imaging in therapeutics

11:00 – 11:20      Warren Chan, UofT

COVID-19 diagnostics via quantum dot barcodes

11:20 – 12:00       Questions & open discussion

Wednesday, March 10th

Session 3: Drug Delivery

9:00 – 9:15      Introduction to PRiME and the Connaught Global Challenge Program

9:15 – 9:35      Ofra Benny, HUJI

Nanomedicine approach for personalized medicine in cancer

9:35 – 9:55      Molly Shoichet, UofT

Affinity-controlled Protein Delivery Strategies

10:00 – 10:20      Abraham J. Domb, HUJI

Injectable Biodegradable Polymers for Regional therapy

10:20 – 10:40      Christine Allen, UofT

Integration of AI into Drug Formulation Development

10:40 – 11:00      Gershon Golomb, HUJI

siRNA lipid nanoparticles for the treatment of herpes simplex

11:00 – 11:20      Omar Khan, UofT

Immunobioengineering through Applied Chemistry

11:20 – 12:00       Questions & open discussion